Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore, Inc. (Nasdaq: ECOR) announced promising results from an Air Force Research Laboratories (AFRL) study on the effectiveness of non-invasive vagus nerve stimulation (nVNS) in accelerating pilot training. The study, conducted at Wright-Patterson Air Force Base, involved 28 participants from the 711th Human Performance Squadron.
Key findings include:
- Significant positive effect of nVNS over sham on day one (37% after trial one, increasing to 51% after trial 12)
- 99% probability that active nVNS was superior to sham on trial 12
- Higher learning rate in the active nVNS group
The research suggests that electroCore's TAC-STIM (nVNS) technology could potentially enhance sensorimotor learning in USAF Simulator Based Pilot Training, marking a significant advancement in military training techniques.
electroCore (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has announced its participation in the 26th Annual H.C. Wainwright Global Investment Conference in New York City from September 9-11, 2024. The company's CEO, Dan Goldberger, will take part in a fireside chat on Wednesday, September 11th, at 12:00 PM ET.
This event provides an opportunity for investors to gain insights into electroCore's operations and future plans. Mr. Goldberger will also be available for one-on-one meetings on the same day, offering a chance for more in-depth discussions with interested parties. The conference serves as a platform for electroCore to showcase its advancements in the field of bioelectronic medicine and wellness to a global investment audience.
Ecora Resources PLC (LSE/TSX:ECOR) announced its half-year results for the six months ended 30 June 2024. Total portfolio contribution increased by 15% year-on-year to $51.3 million, driven by strong performance from the Kestrel steelmaking coal royalty. Adjusted earnings per share rose to 10.38c, up from 9.06c in H1 2023. The company reported a profit before tax of $17.9 million, compared to a loss of $10.2 million in the same period last year.
Ecora declared a half-year dividend of 1.70 cents per share, representing 33% of free cash flow. The company also amended and extended its $150 million revolving credit facility on more favorable terms. Post-period, Ecora acquired a 0.85% Gross Revenue Royalty over the Phalaborwa rare earths project for $8.5 million. However, BHP's decision to temporarily suspend construction of the West Musgrave nickel-copper project was noted as disappointing.
electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, has announced its participation in two upcoming investor conferences. CEO Dan Goldberger will attend the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference from August 12-13, 2024. Interested parties can contact Needham to schedule one-on-one meetings.
Additionally, CFO Brian Posner will be present at the 44th Annual Canaccord Genuity Growth Conference at the InterContinental Hotel in Boston, MA. electroCore will host investor meetings on August 13, 2024. To arrange a meeting, interested parties should contact Canaccord Genuity.
These conferences provide electroCore with opportunities to engage with investors and showcase their commercial-stage bioelectronic medicine and wellness solutions.
electroCore, Inc. (Nasdaq: ECOR) reported its second quarter 2024 financial results, marking its seventh consecutive record quarterly net sales of $6.1 million, a 73% increase from Q2 2023. The company's net loss decreased by 46% to $2.7 million compared to the same period last year. Key highlights include:
- Launch of direct-to-consumer product Truvaga Plus™
- Raised $9.0 million in a Registered Direct Offering
- Joined the Russell Microcap® Index
- Commercial launch of next-generation TAC-STIM™
The company's gross profit increased to $5.3 million with an 86% gross margin. Total operating expenses remained stable at $7.9 million. The significant improvement in financial performance was primarily attributed to the substantial increase in net sales across major channels.
electroCore, Inc. (NASDAQ: ECOR), a bioelectronic medicine and wellness company, has announced the appointment of Stephen Smith as VP of Quality, Regulatory, and Compliance. As part of his employment package, the Compensation Committee granted Smith 10,000 restricted stock units (RSUs) on August 1, 2024. This grant was made as an inducement material under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest over a three-year period, with 33% vesting on each anniversary of the grant date, contingent on Smith's continued employment with electroCore.
electroCore, Inc. (Nasdaq: ECOR) announced positive results from a clinical trial conducted at the Defense Language Institute, demonstrating the effectiveness of non-invasive Vagus Nerve Stimulation (nVNS) in accelerating foreign language learning. The study, published in Scientific Reports, showed that nVNS significantly improved Arabic vocabulary recall compared to sham treatment (p=0.025). Additionally, nVNS participants experienced increased energy (p=0.036) and focus (p=0.001) during training sessions.
The trial involved 36 students from DLI's Arabic school, with 18 receiving nVNS and 18 receiving sham treatment. The nVNS group maintained improved recall even after treatment completion. Dr. Richard McKinley of the Air Force's 711th Human Performance Wing noted that nVNS could be a viable tool to enhance warfighter training and resilience in various areas.
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has announced that it will release its financial results for the second quarter ended June 30, 2024, after the market closes on Wednesday, August 7, 2024. The company will host a conference call and webcast at 4:30 PM EDT on the same day to discuss the financial results and address questions from investors and analysts.
Interested parties can access the conference call by dialing 877-407-8835 (domestic) or +1 201-689-8779 (international) and using the Conference ID: 13744119. A webcast of the earnings call will also be available for those who prefer to listen online.
electroCore has launched TAC-STIM™, an advanced non-invasive vagus nerve stimulator designed for active-duty military use. The device, developed with the US military, aims to enhance human performance by improving focus, reducing fatigue, and accelerating learning by 20-35%. TAC-STIM is portable and uses electroCore's patented technology for precise vagus nerve stimulation. It has been independently tested by the Air Force Research Laboratory and Air Force Special Operations Command, showing reliable performance in various operational settings. TAC-STIM is now available for wholesale purchase.
electroCore (Nasdaq: ECOR) announced its preliminary inclusion in the Russell Microcap® Index. The newly reconstituted indexes will take effect after the market close on June 28, 2024, and begin trading on July 1, 2024, according to a preliminary list by FTSE Russell posted on May 24, 2024. CFO Brian Posner highlighted that this inclusion could boost the company's exposure to investors. The Russell indexes, used by investment managers and institutional investors, benchmark approximately $10.5 trillion in assets. FTSE Russell, a leading global index provider, oversees these indexes.